Our mission

Siloton is on a mission to leverage the latest advancements in integrated photonics to improve the global population’s health.

Our First Target: Preventing Sight loss

AMD impacts 1 in 4 of those over the age of 60. By 2040, it is estimated that there will be 300 million patients globally - that is the same as the entire population of the USA.

20% of these people will have advanced ‘wet’ or neovascular AMD, which is the leading cause of blindness in the developed world. While fast moving, wetAMD can be treated with injections that stabilise the chemical signals that cause abnormal blood vessels to grow. These injections must be given at precise time points to be maximally effective, otherwise abnormal vessels develop and cause sight loss.

There are two problems:

  1. Every patient is different in terms of how often they need an injection, and this need will vary over time.

  2. An eye scan using a machine called an OCT (which stands for optical coherence tomography) is needed to know when an injection is required. These machines are only found in clinics and cannot be accessed frequently.

As a result, eye doctors are forced to balance patient outcomes against treatment burden and resources. They can either bring the patient in for an eye scan every few days to ensure precise timing of injections or perform infrequent scans and look to estimate when patients will require the next treatment.

 

The Solution

Siloton is solving this problem by allowing physicians to regularly monitor their patients between visits to the clinic, so that the physician knows exactly when to arrange an appointment and treat. By developing a new generation of OCT, Siloton is providing a means for the gold-standard imaging technique in ophthalmology to be performed remotely, creating the opportunity for early identification of non-responders and near-to-patient treatment options.